NFL AS A POSSIBLE BIOMARKER OF TREATMENT RESPONSE IN HEREDITARY ATTR AMYLOIDOSIS: DATA FROM THE PATISIRAN APOLLO OLE STUDY

被引：0
|
作者：
Sekijima, Y. [1 ]
Polydefkis, M. [2 ]
Ticau, S. [3 ]
Erbe, D. [3 ]
McManus, A. [3 ]
Aldinc, E. [3 ]
Adams, D. [4 ]
Reilly, M. M. [5 ]
Vaishnaw, A. [3 ]
Nioi, P. [3 ]
机构：
[1] Shinshu Univ Sch Med, Dept Med Neurol & Rheumatol, Nagano, Japan
[2] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[3] Alnylam Pharmaceut, Cambridge, MA USA
[4] Univ Paris Saclay, APHP, CHU Bicetre, INSERM, Le Kremlin Bicetre, France
[5] UCL Queen Sq Inst Neurol, MRC Ctr Neuromuscular Dis, London, England
来源：
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM | 2022年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S12 / S13
页数：2
相关论文
共 50 条
  • [41] PRIMARY RESULTS FROM APOLLO-B OPEN-LABEL EXTENSION STUDY OF PATISIRAN IN PATIENTS WITH TRANSTHYRETIN CARDIAC AMYLOIDOSIS
    Longhi, S.
    Mauer, M.
    Berk, J.
    Hanna, M.
    Gillmore, J.
    Vellosa-schwartzmann, P.
    Lairez, O.
    Hatano, M.
    Cho, H.
    van der Meer, P.
    White, M.
    Yureneva, E.
    Sweetser, M.
    Jay, P.
    Vest, J.
    Fontana, M.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2024, 26 : ii2 - ii2
  • [42] PRIMARY RESULTS FROM APOLLO-B, A PHASE 3 STUDY OF PATISIRAN IN PATIENTS WITH TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH CARDIOMYOPATHY
    Longhi, S.
    Maurer, M.
    Fontana, M.
    Berk, J.
    Gustafsson, F.
    Simoes, M.
    Grogan, M.
    Fernandes, F.
    Gottlieb, R.
    Kubanek, M.
    Poulsen, S.
    Damy, T.
    Diemberger, I.
    Tahara, N.
    Yu, W.
    Tang, W.
    Obici, L.
    Gonzalez-Duarte, A.
    Sekijima, Y.
    White, M.
    Yureneva, E.
    Jay, P.
    Vest, J.
    Gillmore, J.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2023, 25 : D28 - D28
  • [43] PRIMARY RESULTS FROM APOLLO-B, A PHASE 3 STUDY OF PATISIRAN IN PATIENTS WITH TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH CARDIOMYOPATHY
    Longhi, Simone
    Maurer, Mathew S.
    Fontana, Marianna
    Berk, John L.
    Gustafsson, Finn
    Simoes, Marcos
    Grogan, Martha
    Fernandes, Fabio
    Gottlieb, Robert L.
    Kubanek, Milos
    Poulsen, Steen
    Damy, Thibaud
    Diemberger, Igor
    Tahara, Nobuhiro
    Yu, Wen-chuhg
    Tang, W. H. Wilson
    Obici, Laura
    Gonzalez-duarte, Alejandra
    Sekijima, Yoshiki
    White, Matthew T.
    Yureneva, Elena
    Jay, Patrick Y.
    Vest, John
    Gillmore, Julian D.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2022, 24
  • [44] Impact of Patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL-DN) in patients with Hereditary transthyretin-mediated Amyloidosis: results from the Phase-3 APOLLO study
    Obici, L.
    Coelho, T.
    Adams, D.
    Gonzalez-Duarte, A.
    O'riordan, W.
    Yang, C. -C.
    Yamashita, T.
    Kristen, A.
    Tournev, I.
    Schmidt, H.
    Berk, J.
    Lin, K. -P.
    Gandhi, P.
    Sweetser, M.
    Chen, J.
    Goyal, S.
    Gollob, J.
    Suhr, O.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 459 - 459
  • [45] Outcomes of Patients with Hereditary Transthyretin-Mediated Amyloidosis with Early Onset V30M versus all other Mutations in APOLLO, a Phase 3 Study of Patisiran
    Coelho, T.
    Adams, D.
    Gonzalez-Duarte, A.
    O'riordan, W.
    Yang, C. -C.
    Yamashita, T.
    Kristen, A.
    Tournev, I.
    Schmidt, H.
    Berk, J.
    Lin, K. -P.
    Gandhi, P.
    Sweetser, M.
    White, M.
    Goyal, S.
    Gollob, J.
    Suhr, O.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 353 - 354
  • [46] Regression of Cardiac Bone-Tracer Uptake in Patients with Hereditary Transthyretin Amyloidosis after One Year Treatment with Patisiran. An early Marker of Treatment Response?
    Tingen, H.
    Tubben, A.
    Bijzet, J.
    van der Meer, P.
    van den Berg, M. P.
    Houwerzijl, E. J.
    van der Zwaag, P. A.
    Hazenberg, B. P. C.
    Slart, R. H. J.
    Nienhuis, H. L. A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S220 - S221
  • [47] APOLLO-B, a Study of Patisiran in Patients With Transthyretin Cardiac Amyloidosis: Primary LongTerm Results From the Open-Label Extension Period
    Hung, Rebecca R.
    Correia, Edileide D.
    Berk, John L.
    Drachman, Brian
    Fontana, Marianna
    Gillmore, Julian D.
    Mesquita, Claudio T.
    Simoes, Marcus V.
    Yureneva, Elena
    White, Matthew T.
    Sweetser, Marianne T.
    Jay, Patrick Y.
    Vest, John
    Maurer, Mathew S.
    CIRCULATION, 2023, 148
  • [48] EFFECT OF PATISIRAN ON NERVE FIBER DENSITY AND AMYLOID CONTENT IN SKIN: RESULTS FROM PHASE 2 OPEN LABEL EXTENSION (OLE) STUDY IN HATTR AMYLOIDOSIS
    Polydefkis, M.
    Ebenezer, G.
    Adams, D.
    Coelho, T.
    Conceicao, I
    Waddington Cruz, M.
    Schmidt, H.
    Buades, J.
    Campistol, J.
    Pouget, J.
    Berk, J.
    Partisano, A.
    Chen, J.
    Gollob, J.
    Suhr, O.
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2017, 22 (03) : 360 - 360
  • [49] Skin biopsy as biomarker of disease severity in hereditary transthyretin amyloidosis with polyneuropathy: Data from an Italian cohort
    Leonardi, Luca
    Truini, Andrea
    Luigetti, Marco
    Fasolino, Alessandra
    Galosi, Eleonora
    FIonda, Laura
    Vanoli, Fiammetta
    Morino, Stefania
    Antonini, Giovanni
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2020, 25 (04) : 575 - 576
  • [50] Letter by Gonzalez-Costello et al Regarding Article, "Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-mediated Amyloidosis: Analysis of the APOLLO Study"
    Gonzalez-Costello, Jose
    Casasnovas, Carlos
    Diez-Lopez, Carles
    CIRCULATION, 2019, 140 (02) : E90 - E91
12345